LGR6 modulates intervertebral disc degeneration through regulation of macrophage efferocytosis

Intervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix (ECM) degradation, excessive inflammation activation, and increased cell apoptosis. LGR6, a receptor known for its role in tissue regeneration, has recently been implicated in m...

Full description

Saved in:
Bibliographic Details
Published inJournal of translational medicine Vol. 23; no. 1; pp. 475 - 25
Main Authors Li, Fudong, Shi, Yangyang, Chen, Jun, Sun, Jingchuan, Shi, Jiangang, Sun, Kaiqiang, Zheng, Bing
Format Journal Article
LanguageEnglish
Published England BMC 25.04.2025
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Intervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix (ECM) degradation, excessive inflammation activation, and increased cell apoptosis. LGR6, a receptor known for its role in tissue regeneration, has recently been implicated in modulating macrophage efferocytosis, a process critical for clearing apoptotic cells and maintaining tissue homeostasis. This study aimed to investigate the role of LGR6 in regulating IVDD progression and to focus on its impact on macrophage efferocytosis, ECM regulation, and apoptosis in nucleus pulposus cells (NPCs). A comprehensive bioinformatic analysis was performed using datasets GSE56081 and GSE70362 to identify differentially expressed genes (DEGs) and gene modules associated with IVDD. Principal component analysis (PCA), volcano plots, and hierarchical clustering were utilized to assess gene expression patterns. Weighted Gene Co-Expression Network Analysis (WGCNA) was employed to identify gene modules correlated with IVDD, and integrative analysis pinpointed key genes and pathways. In vitro, LGR6 expression in macrophages was manipulated through shRNA interference and overexpression assay. The effects of LGR6 on macrophage efferocytosis, ECM synthesis, and apoptosis were assessed. An in vivo IVDD model was established in mice via disc puncture to evaluate the impact of LGR6 modulation on disc degeneration. Bioinformatic analysis revealed distinct gene expression profiles between control and IVDD samples, with key gene modules identified by WGCNA showing strong correlations with IVDD. Integrative analysis highlighted critical pathways, including ECM-receptor interaction and efferocytosis, that are potentially regulated by several key genes including SERPINA1, THBS4, ELMO1, LGR6, and ITGB8. Of those genes, LGR6 appeared to be the gene most closely related to IVDD severity. In addition, the mRNA level and protein level of LGR6 in macrophages co-cultured with IL-1β-treated NPCs were raised significantly, compared to the control group. In vitro, LGR6 overexpression enhanced macrophage efferocytosis. Meanwhile, under co-culturing with IL-1β-treated NPCs, LGR6 overexpression in macrophages led to increased expression of ECM components such as COL2A1 and decreased expression of matrix-degrading enzymes like MMP13, indicating a protective effect against matrix degradation. Additionally, LGR6 overexpression inhibited IL-1β-induced apoptosis in NPCs by upregulating anti-apoptotic proteins (BCL2) and downregulating pro-apoptotic markers (cleaved caspase 3 and BAX). Conversely, LGR6 knockdown impaired macrophage efferocytosis and exacerbated NPCs apoptosis. In the mouse IVDD model, promoting efferocytosis resulted in improved ECM integrity and reduced apoptosis; and suppressing efferocytosis caused opposite effect, further supporting the protective role of LGR6-related efferocytosis in IVDD. LGR6 significantly contributes to the protective effects on IVDD by modulating macrophage efferocytosis, enhancing ECM synthesis, and reducing apoptosis in NPCs. These findings highlight that LGR6 could be a promising therapeutic target for IVDD, with its dual role in regulating immune responses and preserving tissue integrity. Future studies are necessary to evaluate the clinical potential of LGR6-based therapies in treating degenerative disc diseases.
AbstractList Intervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix (ECM) degradation, excessive inflammation activation, and increased cell apoptosis. LGR6, a receptor known for its role in tissue regeneration, has recently been implicated in modulating macrophage efferocytosis, a process critical for clearing apoptotic cells and maintaining tissue homeostasis. This study aimed to investigate the role of LGR6 in regulating IVDD progression and to focus on its impact on macrophage efferocytosis, ECM regulation, and apoptosis in nucleus pulposus cells (NPCs).BACKGROUND AND OBJECTIVESIntervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix (ECM) degradation, excessive inflammation activation, and increased cell apoptosis. LGR6, a receptor known for its role in tissue regeneration, has recently been implicated in modulating macrophage efferocytosis, a process critical for clearing apoptotic cells and maintaining tissue homeostasis. This study aimed to investigate the role of LGR6 in regulating IVDD progression and to focus on its impact on macrophage efferocytosis, ECM regulation, and apoptosis in nucleus pulposus cells (NPCs).A comprehensive bioinformatic analysis was performed using datasets GSE56081 and GSE70362 to identify differentially expressed genes (DEGs) and gene modules associated with IVDD. Principal component analysis (PCA), volcano plots, and hierarchical clustering were utilized to assess gene expression patterns. Weighted Gene Co-Expression Network Analysis (WGCNA) was employed to identify gene modules correlated with IVDD, and integrative analysis pinpointed key genes and pathways. In vitro, LGR6 expression in macrophages was manipulated through shRNA interference and overexpression assay. The effects of LGR6 on macrophage efferocytosis, ECM synthesis, and apoptosis were assessed. An in vivo IVDD model was established in mice via disc puncture to evaluate the impact of LGR6 modulation on disc degeneration.METHODSA comprehensive bioinformatic analysis was performed using datasets GSE56081 and GSE70362 to identify differentially expressed genes (DEGs) and gene modules associated with IVDD. Principal component analysis (PCA), volcano plots, and hierarchical clustering were utilized to assess gene expression patterns. Weighted Gene Co-Expression Network Analysis (WGCNA) was employed to identify gene modules correlated with IVDD, and integrative analysis pinpointed key genes and pathways. In vitro, LGR6 expression in macrophages was manipulated through shRNA interference and overexpression assay. The effects of LGR6 on macrophage efferocytosis, ECM synthesis, and apoptosis were assessed. An in vivo IVDD model was established in mice via disc puncture to evaluate the impact of LGR6 modulation on disc degeneration.Bioinformatic analysis revealed distinct gene expression profiles between control and IVDD samples, with key gene modules identified by WGCNA showing strong correlations with IVDD. Integrative analysis highlighted critical pathways, including ECM-receptor interaction and efferocytosis, that are potentially regulated by several key genes including SERPINA1, THBS4, ELMO1, LGR6, and ITGB8. Of those genes, LGR6 appeared to be the gene most closely related to IVDD severity. In addition, the mRNA level and protein level of LGR6 in macrophages co-cultured with IL-1β-treated NPCs were raised significantly, compared to the control group. In vitro, LGR6 overexpression enhanced macrophage efferocytosis. Meanwhile, under co-culturing with IL-1β-treated NPCs, LGR6 overexpression in macrophages led to increased expression of ECM components such as COL2A1 and decreased expression of matrix-degrading enzymes like MMP13, indicating a protective effect against matrix degradation. Additionally, LGR6 overexpression inhibited IL-1β-induced apoptosis in NPCs by upregulating anti-apoptotic proteins (BCL2) and downregulating pro-apoptotic markers (cleaved caspase 3 and BAX). Conversely, LGR6 knockdown impaired macrophage efferocytosis and exacerbated NPCs apoptosis. In the mouse IVDD model, promoting efferocytosis resulted in improved ECM integrity and reduced apoptosis; and suppressing efferocytosis caused opposite effect, further supporting the protective role of LGR6-related efferocytosis in IVDD.RESULTSBioinformatic analysis revealed distinct gene expression profiles between control and IVDD samples, with key gene modules identified by WGCNA showing strong correlations with IVDD. Integrative analysis highlighted critical pathways, including ECM-receptor interaction and efferocytosis, that are potentially regulated by several key genes including SERPINA1, THBS4, ELMO1, LGR6, and ITGB8. Of those genes, LGR6 appeared to be the gene most closely related to IVDD severity. In addition, the mRNA level and protein level of LGR6 in macrophages co-cultured with IL-1β-treated NPCs were raised significantly, compared to the control group. In vitro, LGR6 overexpression enhanced macrophage efferocytosis. Meanwhile, under co-culturing with IL-1β-treated NPCs, LGR6 overexpression in macrophages led to increased expression of ECM components such as COL2A1 and decreased expression of matrix-degrading enzymes like MMP13, indicating a protective effect against matrix degradation. Additionally, LGR6 overexpression inhibited IL-1β-induced apoptosis in NPCs by upregulating anti-apoptotic proteins (BCL2) and downregulating pro-apoptotic markers (cleaved caspase 3 and BAX). Conversely, LGR6 knockdown impaired macrophage efferocytosis and exacerbated NPCs apoptosis. In the mouse IVDD model, promoting efferocytosis resulted in improved ECM integrity and reduced apoptosis; and suppressing efferocytosis caused opposite effect, further supporting the protective role of LGR6-related efferocytosis in IVDD.LGR6 significantly contributes to the protective effects on IVDD by modulating macrophage efferocytosis, enhancing ECM synthesis, and reducing apoptosis in NPCs. These findings highlight that LGR6 could be a promising therapeutic target for IVDD, with its dual role in regulating immune responses and preserving tissue integrity. Future studies are necessary to evaluate the clinical potential of LGR6-based therapies in treating degenerative disc diseases.CONCLUSIONSLGR6 significantly contributes to the protective effects on IVDD by modulating macrophage efferocytosis, enhancing ECM synthesis, and reducing apoptosis in NPCs. These findings highlight that LGR6 could be a promising therapeutic target for IVDD, with its dual role in regulating immune responses and preserving tissue integrity. Future studies are necessary to evaluate the clinical potential of LGR6-based therapies in treating degenerative disc diseases.
Intervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix (ECM) degradation, excessive inflammation activation, and increased cell apoptosis. LGR6, a receptor known for its role in tissue regeneration, has recently been implicated in modulating macrophage efferocytosis, a process critical for clearing apoptotic cells and maintaining tissue homeostasis. This study aimed to investigate the role of LGR6 in regulating IVDD progression and to focus on its impact on macrophage efferocytosis, ECM regulation, and apoptosis in nucleus pulposus cells (NPCs). A comprehensive bioinformatic analysis was performed using datasets GSE56081 and GSE70362 to identify differentially expressed genes (DEGs) and gene modules associated with IVDD. Principal component analysis (PCA), volcano plots, and hierarchical clustering were utilized to assess gene expression patterns. Weighted Gene Co-Expression Network Analysis (WGCNA) was employed to identify gene modules correlated with IVDD, and integrative analysis pinpointed key genes and pathways. In vitro, LGR6 expression in macrophages was manipulated through shRNA interference and overexpression assay. The effects of LGR6 on macrophage efferocytosis, ECM synthesis, and apoptosis were assessed. An in vivo IVDD model was established in mice via disc puncture to evaluate the impact of LGR6 modulation on disc degeneration. Bioinformatic analysis revealed distinct gene expression profiles between control and IVDD samples, with key gene modules identified by WGCNA showing strong correlations with IVDD. Integrative analysis highlighted critical pathways, including ECM-receptor interaction and efferocytosis, that are potentially regulated by several key genes including SERPINA1, THBS4, ELMO1, LGR6, and ITGB8. Of those genes, LGR6 appeared to be the gene most closely related to IVDD severity. In addition, the mRNA level and protein level of LGR6 in macrophages co-cultured with IL-1β-treated NPCs were raised significantly, compared to the control group. In vitro, LGR6 overexpression enhanced macrophage efferocytosis. Meanwhile, under co-culturing with IL-1β-treated NPCs, LGR6 overexpression in macrophages led to increased expression of ECM components such as COL2A1 and decreased expression of matrix-degrading enzymes like MMP13, indicating a protective effect against matrix degradation. Additionally, LGR6 overexpression inhibited IL-1β-induced apoptosis in NPCs by upregulating anti-apoptotic proteins (BCL2) and downregulating pro-apoptotic markers (cleaved caspase 3 and BAX). Conversely, LGR6 knockdown impaired macrophage efferocytosis and exacerbated NPCs apoptosis. In the mouse IVDD model, promoting efferocytosis resulted in improved ECM integrity and reduced apoptosis; and suppressing efferocytosis caused opposite effect, further supporting the protective role of LGR6-related efferocytosis in IVDD. LGR6 significantly contributes to the protective effects on IVDD by modulating macrophage efferocytosis, enhancing ECM synthesis, and reducing apoptosis in NPCs. These findings highlight that LGR6 could be a promising therapeutic target for IVDD, with its dual role in regulating immune responses and preserving tissue integrity. Future studies are necessary to evaluate the clinical potential of LGR6-based therapies in treating degenerative disc diseases.
Abstract Background and objectives Intervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix (ECM) degradation, excessive inflammation activation, and increased cell apoptosis. LGR6, a receptor known for its role in tissue regeneration, has recently been implicated in modulating macrophage efferocytosis, a process critical for clearing apoptotic cells and maintaining tissue homeostasis. This study aimed to investigate the role of LGR6 in regulating IVDD progression and to focus on its impact on macrophage efferocytosis, ECM regulation, and apoptosis in nucleus pulposus cells (NPCs). Methods A comprehensive bioinformatic analysis was performed using datasets GSE56081 and GSE70362 to identify differentially expressed genes (DEGs) and gene modules associated with IVDD. Principal component analysis (PCA), volcano plots, and hierarchical clustering were utilized to assess gene expression patterns. Weighted Gene Co-Expression Network Analysis (WGCNA) was employed to identify gene modules correlated with IVDD, and integrative analysis pinpointed key genes and pathways. In vitro, LGR6 expression in macrophages was manipulated through shRNA interference and overexpression assay. The effects of LGR6 on macrophage efferocytosis, ECM synthesis, and apoptosis were assessed. An in vivo IVDD model was established in mice via disc puncture to evaluate the impact of LGR6 modulation on disc degeneration. Results Bioinformatic analysis revealed distinct gene expression profiles between control and IVDD samples, with key gene modules identified by WGCNA showing strong correlations with IVDD. Integrative analysis highlighted critical pathways, including ECM-receptor interaction and efferocytosis, that are potentially regulated by several key genes including SERPINA1, THBS4, ELMO1, LGR6, and ITGB8. Of those genes, LGR6 appeared to be the gene most closely related to IVDD severity. In addition, the mRNA level and protein level of LGR6 in macrophages co-cultured with IL-1β-treated NPCs were raised significantly, compared to the control group. In vitro, LGR6 overexpression enhanced macrophage efferocytosis. Meanwhile, under co-culturing with IL-1β-treated NPCs, LGR6 overexpression in macrophages led to increased expression of ECM components such as COL2A1 and decreased expression of matrix-degrading enzymes like MMP13, indicating a protective effect against matrix degradation. Additionally, LGR6 overexpression inhibited IL-1β-induced apoptosis in NPCs by upregulating anti-apoptotic proteins (BCL2) and downregulating pro-apoptotic markers (cleaved caspase 3 and BAX). Conversely, LGR6 knockdown impaired macrophage efferocytosis and exacerbated NPCs apoptosis. In the mouse IVDD model, promoting efferocytosis resulted in improved ECM integrity and reduced apoptosis; and suppressing efferocytosis caused opposite effect, further supporting the protective role of LGR6-related efferocytosis in IVDD. Conclusions LGR6 significantly contributes to the protective effects on IVDD by modulating macrophage efferocytosis, enhancing ECM synthesis, and reducing apoptosis in NPCs. These findings highlight that LGR6 could be a promising therapeutic target for IVDD, with its dual role in regulating immune responses and preserving tissue integrity. Future studies are necessary to evaluate the clinical potential of LGR6-based therapies in treating degenerative disc diseases.
ArticleNumber 475
Author Sun, Jingchuan
Zheng, Bing
Shi, Yangyang
Sun, Kaiqiang
Chen, Jun
Li, Fudong
Shi, Jiangang
Author_xml – sequence: 1
  givenname: Fudong
  surname: Li
  fullname: Li, Fudong
– sequence: 2
  givenname: Yangyang
  surname: Shi
  fullname: Shi, Yangyang
– sequence: 3
  givenname: Jun
  surname: Chen
  fullname: Chen, Jun
– sequence: 4
  givenname: Jingchuan
  surname: Sun
  fullname: Sun, Jingchuan
– sequence: 5
  givenname: Jiangang
  surname: Shi
  fullname: Shi, Jiangang
– sequence: 6
  givenname: Kaiqiang
  surname: Sun
  fullname: Sun, Kaiqiang
– sequence: 7
  givenname: Bing
  surname: Zheng
  fullname: Zheng, Bing
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40281518$$D View this record in MEDLINE/PubMed
BookMark eNpNkUtr3TAQhUVJaR7tH-iieNmNU708kpYltGngQqG02wpJHvk62NatJBfy7-ubm4as5jB8cwbOuSRnS1qQkPeMXjOm4VNh3IBqKe9aCpJv6hW5YFKZttMKzl7oc3JZyj2lXHbSvCHnknLNOqYvyO_d7Q9o5tSvk6tYmnGpmP9iruizm5p-LKHpccAFs6tjWpq6z2kd9k3G4XhyXKXYzC7kdNi7ARuMEXMKDzWVsbwlr6ObCr57mlfk19cvP2--tbvvt3c3n3dtEAC1FcJ0nAYHXhsqmJOeShBGGS4DeIGqFxRUMNJFFZ1gRjmvPCgNiBJiEFfk7uTbJ3dvD3mcXX6wyY32cZHyYF2uY5jQcuepcgakiSC1jF5FioIK3WMIjOrN6-PJ65DTnxVLtfOWAk6TWzCtxW7vOwUAHdvQD0_o6mfsnx__z3cD-AnY4iklY3xGGLXHEu2pRLuVaB9LtFT8A93WjyA
Cites_doi 10.1111/exd.13187
10.1042/BSR20182375
10.1186/s11658-023-00517-x
10.7150/thno.78878
10.1016/j.immuni.2022.11.013
10.1016/S0140-6736(21)00733-9
10.1074/jbc.RA118.006628
10.1152/ajplung.00066.2012
10.1080/15548627.2023.2186099
10.1016/j.jad.2024.02.045
10.1182/blood-2010-02-272005
10.1038/s41388-021-02002-1
10.1038/ng.3957
10.1039/D0FO03353G
10.1016/S0140-6736(16)30970-9
10.1016/j.intimp.2022.108671
10.1136/annrheumdis-2021-221513
10.1016/j.neuron.2022.10.015
10.7150/thno.90370
10.1038/s41590-018-0249-1
10.1038/srep15662
10.1016/j.jconrel.2024.03.029
10.1186/s12943-019-1022-2
10.1016/j.bone.2023.116681
10.1302/2046-3758.121.BJR-2022-0225.R1
10.1186/s12951-023-02075-y
10.7554/eLife.83069
10.1016/j.bone.2024.117207
10.1016/j.jaci.2015.07.034
10.1016/j.stem.2021.05.007
10.7150/thno.93036
10.7150/thno.48987
10.1016/j.carbpol.2020.116757
10.3389/fmed.2021.676688
10.1074/jbc.M114.570838
10.1371/journal.pone.0127885
10.1016/j.atherosclerosis.2019.04.229
10.1016/j.omto.2019.04.002
10.1016/j.redox.2023.102763
10.1111/acel.13072
10.1039/D3FO01902K
10.1007/s10072-021-05835-6
10.1093/rheumatology/keab096
10.1038/s42255-023-00736-8
10.1002/adma.202313248
10.15252/emmm.202317815
10.1038/s41467-024-44886-z
ContentType Journal Article
Copyright 2025. The Author(s).
Copyright_xml – notice: 2025. The Author(s).
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOA
DOI 10.1186/s12967-025-06427-0
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE

Database_xml – sequence: 1
  dbid: DOA
  name: Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1479-5876
EndPage 25
ExternalDocumentID oai_doaj_org_article_2ab07a9649f6484fb7f0e3038decc108
40281518
10_1186_s12967_025_06427_0
Genre Journal Article
GrantInformation_xml – fundername: Shanghai Sailing Program
  grantid: 23YF1459100
– fundername: National Natural Science Foundation of China
  grantid: 82472493
– fundername: National Natural Science Foundation of China
  grantid: 82172381
– fundername: High Achievement Cultivation Plan of Changzheng Hospital
  grantid: 2020YCGPZ106
– fundername: National Natural Science Foundation of China
  grantid: 82302760
– fundername: Shanghai Municipal Hospital Development Center
  grantid: SHDC2020CR1024B
GroupedDBID ---
0R~
29L
2WC
53G
5VS
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACUHS
ADBBV
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
CGR
CUY
CVF
ECM
EIF
NPM
7X8
PUEGO
ID FETCH-LOGICAL-c366t-339520ca6b89031a4b046397924c6b3e7d3067c94af7fa3197ab7b6786ee46fc3
IEDL.DBID DOA
ISSN 1479-5876
IngestDate Wed Aug 27 00:23:26 EDT 2025
Fri Jul 11 18:30:44 EDT 2025
Mon Jul 21 05:46:05 EDT 2025
Tue Aug 05 12:13:31 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Efferocytosis
Intervertebral disc degeneration
Nucleus pulposus
LGR6
Macrophages
Apoptosis
Language English
License 2025. The Author(s).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c366t-339520ca6b89031a4b046397924c6b3e7d3067c94af7fa3197ab7b6786ee46fc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doaj.org/article/2ab07a9649f6484fb7f0e3038decc108
PMID 40281518
PQID 3195766651
PQPubID 23479
PageCount 25
ParticipantIDs doaj_primary_oai_doaj_org_article_2ab07a9649f6484fb7f0e3038decc108
proquest_miscellaneous_3195766651
pubmed_primary_40281518
crossref_primary_10_1186_s12967_025_06427_0
PublicationCentury 2000
PublicationDate 2025-04-25
PublicationDateYYYYMMDD 2025-04-25
PublicationDate_xml – month: 04
  year: 2025
  text: 2025-04-25
  day: 25
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle Journal of translational medicine
PublicationTitleAlternate J Transl Med
PublicationYear 2025
Publisher BMC
Publisher_xml – name: BMC
References Z Kamali Amir (6427_CR10) 2021; 11
K Rovati Lucrezia (6427_CR35) 2021; 60
KN Nick (6427_CR1) 2021; 398
S Yoshida (6427_CR17) 2012; 303
G Romero-Molina Carmen (6427_CR30) 2022; 110
D Laura (6427_CR36) 2023; 169
H Wang Xiaochen (6427_CR23) 2023; 56
D Wang (6427_CR46) 2023; 19
L Feng Qian (6427_CR40) 2021; 40
M Xie Chenglong (6427_CR21) 2021; 12
M Lei (6427_CR11) 2023; 28
T Nash William (6427_CR22) 2021; 8
S Zhao Xin (6427_CR5) 2023; 21
N Schilperoort Maaike (6427_CR6) 2023; 5
V Myers Kayla (6427_CR31) 2019; 18
T Elder Craig (6427_CR42) 2021; 35
Y Xiao (6427_CR18) 2024; 352
L Kourtzelis Ioannis (6427_CR24) 2019; 20
B Li (6427_CR8) 2023; 13
WM-YG Yun-Jun (6427_CR25) 2023; 15
O Liu Xiong (6427_CR27) 2024; 369
W Jiang Lichun (6427_CR38) 2017; 26
S King Justin (6427_CR39) 2024; 187
R Fernandez-Boyanapalli (6427_CR16) 2010; 116
S Xu Jiawen (6427_CR3) 2023; 12
Q Feng (6427_CR48) 2021; 40
J Fan Linfeng (6427_CR32) 2024; 14
Y Zihao (6427_CR26) 2023; 12
K Huang Sixia (6427_CR37) 2021; 28
Y Nishi Chihiro (6427_CR7) 2019; 294
F Jiang Yanhai (6427_CR4) 2019; 39
X Ruan (6427_CR49) 2019; 14
M Zhaoxin (6427_CR20) 2022; 107
F Wang (6427_CR45) 2018; 42
Z Kazezian (6427_CR12) 2015; 5
K Sun (6427_CR13) 2024; 36
6427_CR15
G Singh (6427_CR19) 2020; 247
KJ-M Quan Hui (6427_CR34) 2015; 10
N Nguyen Khanh-Quynh (6427_CR33) 2014; 289
R Ma Tianwen (6427_CR41) 2023; 14
M-N Saiko (6427_CR14) 2019; 286
U Maher Chris (6427_CR2) 2017; 389
Y Huang Phillips (6427_CR43) 2017; 49
6427_CR29
T Taheri Forough (6427_CR9) 2022; 43
L Wang Yue (6427_CR28) 2023; 64
D Kim (6427_CR44) 2020; 19
H Zhang (6427_CR47) 2022; 81
C Cohen (6427_CR50) 2024; 15
References_xml – volume: 26
  start-page: 105
  issue: 2
  year: 2017
  ident: 6427_CR38
  publication-title: Exp Dermatol
  doi: 10.1111/exd.13187
– volume: 39
  start-page: BSR20182375
  issue: 2
  year: 2019
  ident: 6427_CR4
  publication-title: Biosci Rep
  doi: 10.1042/BSR20182375
– volume: 28
  start-page: 104
  year: 2023
  ident: 6427_CR11
  publication-title: Cell Mol Biol Lett
  doi: 10.1186/s11658-023-00517-x
– volume: 13
  start-page: 231
  issue: 1
  year: 2023
  ident: 6427_CR8
  publication-title: Theranostics
  doi: 10.7150/thno.78878
– volume: 56
  start-page: 58
  issue: 1
  year: 2023
  ident: 6427_CR23
  publication-title: Immunity
  doi: 10.1016/j.immuni.2022.11.013
– volume: 398
  start-page: 78
  issue: 10294
  year: 2021
  ident: 6427_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)00733-9
– volume: 294
  start-page: 7221
  issue: 18
  year: 2019
  ident: 6427_CR7
  publication-title: J Biol Chem
  doi: 10.1074/jbc.RA118.006628
– volume: 303
  start-page: L852
  year: 2012
  ident: 6427_CR17
  publication-title: Am J Physiol Lung Cell Mol Physiol
  doi: 10.1152/ajplung.00066.2012
– volume: 19
  start-page: 2485
  issue: 9
  year: 2023
  ident: 6427_CR46
  publication-title: Autophagy
  doi: 10.1080/15548627.2023.2186099
– volume: 352
  start-page: 76
  year: 2024
  ident: 6427_CR18
  publication-title: J Affect Disord
  doi: 10.1016/j.jad.2024.02.045
– volume: 116
  start-page: 4512
  year: 2010
  ident: 6427_CR16
  publication-title: Blood
  doi: 10.1182/blood-2010-02-272005
– volume: 40
  start-page: 6103
  issue: 42
  year: 2021
  ident: 6427_CR48
  publication-title: Oncogene
  doi: 10.1038/s41388-021-02002-1
– volume: 49
  start-page: 1624
  issue: 11
  year: 2017
  ident: 6427_CR43
  publication-title: Nat Genet
  doi: 10.1038/ng.3957
– volume: 12
  start-page: 2703
  issue: 6
  year: 2021
  ident: 6427_CR21
  publication-title: Food Funct
  doi: 10.1039/D0FO03353G
– volume: 389
  start-page: 736
  issue: 10070
  year: 2017
  ident: 6427_CR2
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)30970-9
– volume: 107
  start-page: 108671
  year: 2022
  ident: 6427_CR20
  publication-title: Int Immunopharmacol
  doi: 10.1016/j.intimp.2022.108671
– volume: 81
  start-page: 676
  issue: 5
  year: 2022
  ident: 6427_CR47
  publication-title: Ann Rheum Dis
  doi: 10.1136/annrheumdis-2021-221513
– volume: 110
  start-page: 3513
  issue: 21
  year: 2022
  ident: 6427_CR30
  publication-title: Neuron
  doi: 10.1016/j.neuron.2022.10.015
– volume: 14
  start-page: 283
  issue: 1
  year: 2024
  ident: 6427_CR32
  publication-title: Theranostics
  doi: 10.7150/thno.90370
– volume: 20
  start-page: 40
  issue: 1
  year: 2019
  ident: 6427_CR24
  publication-title: Nat Immunol
  doi: 10.1038/s41590-018-0249-1
– volume: 5
  start-page: 15662
  year: 2015
  ident: 6427_CR12
  publication-title: Sci Rep
  doi: 10.1038/srep15662
– volume: 369
  start-page: 215
  year: 2024
  ident: 6427_CR27
  publication-title: J Control Release
  doi: 10.1016/j.jconrel.2024.03.029
– volume: 18
  start-page: 94
  issue: 1
  year: 2019
  ident: 6427_CR31
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1022-2
– volume: 169
  start-page: 116681
  year: 2023
  ident: 6427_CR36
  publication-title: Bone
  doi: 10.1016/j.bone.2023.116681
– volume: 12
  start-page: 80
  issue: 1
  year: 2023
  ident: 6427_CR3
  publication-title: Bone Joint Res
  doi: 10.1302/2046-3758.121.BJR-2022-0225.R1
– volume: 21
  start-page: 317
  issue: 1
  year: 2023
  ident: 6427_CR5
  publication-title: J Nanobiotechnol
  doi: 10.1186/s12951-023-02075-y
– volume: 12
  start-page: e83069
  year: 2023
  ident: 6427_CR26
  publication-title: Elife
  doi: 10.7554/eLife.83069
– volume: 187
  start-page: 117207
  year: 2024
  ident: 6427_CR39
  publication-title: Bone
  doi: 10.1016/j.bone.2024.117207
– ident: 6427_CR15
  doi: 10.1016/j.jaci.2015.07.034
– volume: 40
  start-page: 6103
  issue: 42
  year: 2021
  ident: 6427_CR40
  publication-title: Oncogene
  doi: 10.1038/s41388-021-02002-1
– volume: 35
  start-page: e21780
  issue: 8
  year: 2021
  ident: 6427_CR42
  publication-title: FASEB J
– volume: 28
  start-page: 1582
  issue: 9
  year: 2021
  ident: 6427_CR37
  publication-title: Cell Stem Cell
  doi: 10.1016/j.stem.2021.05.007
– volume: 42
  start-page: 625
  issue: 1
  year: 2018
  ident: 6427_CR45
  publication-title: Int J Mol Med
– ident: 6427_CR29
  doi: 10.7150/thno.93036
– volume: 11
  start-page: 27
  issue: 1
  year: 2021
  ident: 6427_CR10
  publication-title: Theranostics
  doi: 10.7150/thno.48987
– volume: 247
  start-page: 116757
  year: 2020
  ident: 6427_CR19
  publication-title: Carbohydr Polym
  doi: 10.1016/j.carbpol.2020.116757
– volume: 8
  start-page: 676688
  year: 2021
  ident: 6427_CR22
  publication-title: Front Med (Lausanne)
  doi: 10.3389/fmed.2021.676688
– volume: 289
  start-page: 25737
  issue: 37
  year: 2014
  ident: 6427_CR33
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M114.570838
– volume: 10
  start-page: e0127885
  issue: 5
  year: 2015
  ident: 6427_CR34
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0127885
– volume: 286
  start-page: 30
  year: 2019
  ident: 6427_CR14
  publication-title: Atherosclerosis
  doi: 10.1016/j.atherosclerosis.2019.04.229
– volume: 14
  start-page: 94
  year: 2019
  ident: 6427_CR49
  publication-title: Mol Ther Oncolytics
  doi: 10.1016/j.omto.2019.04.002
– volume: 64
  start-page: 102763
  year: 2023
  ident: 6427_CR28
  publication-title: Redox Biol
  doi: 10.1016/j.redox.2023.102763
– volume: 19
  start-page: e13072
  issue: 3
  year: 2020
  ident: 6427_CR44
  publication-title: Aging Cell
  doi: 10.1111/acel.13072
– volume: 14
  start-page: 9999
  issue: 22
  year: 2023
  ident: 6427_CR41
  publication-title: Food Funct
  doi: 10.1039/D3FO01902K
– volume: 43
  start-page: 1593
  issue: 3
  year: 2022
  ident: 6427_CR9
  publication-title: Neurol Sci
  doi: 10.1007/s10072-021-05835-6
– volume: 60
  start-page: 4929
  issue: 10
  year: 2021
  ident: 6427_CR35
  publication-title: Rheumatology (Oxford)
  doi: 10.1093/rheumatology/keab096
– volume: 5
  start-page: 431
  issue: 3
  year: 2023
  ident: 6427_CR6
  publication-title: Nat Metab
  doi: 10.1038/s42255-023-00736-8
– volume: 36
  start-page: e2313248
  issue: 19
  year: 2024
  ident: 6427_CR13
  publication-title: Adv Mater
  doi: 10.1002/adma.202313248
– volume: 15
  start-page: e17815
  issue: 12
  year: 2023
  ident: 6427_CR25
  publication-title: EMBO Mol Med
  doi: 10.15252/emmm.202317815
– volume: 15
  start-page: 743
  issue: 1
  year: 2024
  ident: 6427_CR50
  publication-title: Nat Commun
  doi: 10.1038/s41467-024-44886-z
SSID ssj0024549
Score 2.4296296
Snippet Intervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix (ECM) degradation, excessive...
Abstract Background and objectives Intervertebral disc degeneration (IVDD) is a leading cause of chronic low back pain, characterized by extracellular matrix...
SourceID doaj
proquest
pubmed
crossref
SourceType Open Website
Aggregation Database
Index Database
StartPage 475
SubjectTerms Animals
Apoptosis
Apoptosis - genetics
Efferocytosis
Extracellular Matrix - metabolism
Gene Expression Profiling
Gene Expression Regulation
Gene Regulatory Networks
Humans
Intervertebral disc degeneration
Intervertebral Disc Degeneration - genetics
Intervertebral Disc Degeneration - metabolism
Intervertebral Disc Degeneration - pathology
LGR6
Macrophages
Macrophages - metabolism
Macrophages - pathology
Male
Mice
Nucleus pulposus
Nucleus Pulposus - metabolism
Nucleus Pulposus - pathology
Phagocytosis
Receptors, G-Protein-Coupled - genetics
Receptors, G-Protein-Coupled - metabolism
Title LGR6 modulates intervertebral disc degeneration through regulation of macrophage efferocytosis
URI https://www.ncbi.nlm.nih.gov/pubmed/40281518
https://www.proquest.com/docview/3195766651
https://doaj.org/article/2ab07a9649f6484fb7f0e3038decc108
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1JS8QwFA4uIF7E3XEZIniTYpc0y9ERF0RFBoXBgyFJUx3QqUzrwX_vS9KKHsSLl1JKIOn38paPvLyH0EGe2pSovABFMnFEEq0iTgSLUnAtieLCMOWzfG_oxT25HOWjb62-XE5YKA8cgDtKlY6ZEpSIkhJOSs3K2ILd5QVMnoRrvuDzOjLVVdkD2tNdkeH0qAavBgbBtW51ATe8_XBDvlr_7yGmdzVny2ipjRHxcVjbCpqxk1W0cN2egq-hx6vzIcWvVeFab9kaj0Pe4rRxh8Av2F20xYV98gWlHe64bcaDp6HxvPtUlfhVufZdz2BQsMvqAE_20VT1uF5H92endycXUdsnITIZpU2UZSJPY6Oo5gJ0VBHtyoAJBtTKUJ1ZVjheYARRJSsV6BxTmmnwUtRaQkuTbaC5STWxWwgrARaQaZObuCSGWSBDoMAmyTVMQHncQ4cdbPItlMOQnkZwKgPIEkCWHmQJowcO2a-RrpS1_wAClq2A5V8C7qH9Ti4Str47z1ATW73XEv4E2BKledJDm0FgX1MBLeYQzPDt_1jCDlpM_d4hUZrvorlm-m73IBZpdB_NshHro_nB6c3tsO83ITyHg4dP7F_d1g
linkProvider Directory of Open Access Journals
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=LGR6+modulates+intervertebral+disc+degeneration+through+regulation+of+macrophage+efferocytosis&rft.jtitle=Journal+of+translational+medicine&rft.au=Li%2C+Fudong&rft.au=Shi%2C+Yangyang&rft.au=Chen%2C+Jun&rft.au=Sun%2C+Jingchuan&rft.date=2025-04-25&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=23&rft.issue=1&rft.spage=475&rft_id=info:doi/10.1186%2Fs12967-025-06427-0&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon